Protease-Based Subunit Vaccine in Mice Boosts BCG Protection against Mycobacterium tuberculosis
Vaccines, 2022 The significant number of people with latent and active tuberculosis infection requires further efforts to develop new vaccines or improve the Bacillus Calmette-Guérin (BCG), which is the only approved vaccine against this disease.
Ana Paula Junqueira-Kipnis +7 more
doaj +1 more source
Vaccine-Induced Subcutaneous Granulomas in Goats Reflect Differences in Host-Mycobacterium Interactions between BCG- and Recombinant BCG-Derivative Vaccines. [PDF]
Int J Mol Sci, 2022 Tuberculous granulomas are highly dynamic structures reflecting the complex host–mycobacterium interactions. The objective of this study was to compare granuloma development at the site of vaccination with BCG and its recombinant derivatives in goats.
Liebler-Tenorio EM +9 more
europepmc +6 more sources
The use of directed evolution to create a stable and immunogenic recombinant BCG expressing a modified HIV-1 Gag antigen. [PDF]
PLoS ONE, 2014 Numerous features make Mycobacterium bovis BCG an attractive vaccine vector for HIV. It has a good safety profile, it elicits long-lasting cellular immune responses and in addition manufacturing costs are affordable.
Rosamund Chapman +8 more
doaj +1 more source
Vaccines, 2021 The only currently available anti-tuberculosis vaccine, Bacillus Calmette–Guérin (BCG), has been reported to also protect against unrelated diseases, including inflammatory diseases such as allergic asthma. Recombinant BCG strains that produce IL-18 have
Magdalena Kowalewicz-Kulbat +7 more
doaj +1 more source
Protective efficacy of BCG overexpressing an L,D-transpeptidase against M. tuberculosis infection. [PDF]
PLoS ONE, 2010 M. bovis Bacille Calmette-Guérin (BCG), currently the only available vaccine against tuberculosis (TB), fails to adequately protect individuals from active and latent TB infection.
Scott T Nolan, Gyanu Lamichhane
doaj +1 more source
New use of BCG for recombinant vaccines [PDF]
Nature, 1991 BCG, a live attenuated tubercle bacillus, is the most widely used vaccine in the world and is also a useful vaccine vehicle for delivering protective antigens of multiple pathogens. Extrachromosomal and integrative expression vectors carrying the regulatory sequences for major BCG heat-shock proteins have been developed to allow expression of foreign ...
C. K. Stover +13 more
openaire +2 more sources
The glycosylated Rv1860 protein of Mycobacterium tuberculosis inhibits dendritic cell mediated TH1 and TH17 polarization of T cells and abrogates protective immunity conferred by BCG. [PDF]
PLoS Pathogens, 2014 We previously reported interferon gamma secretion by human CD4⁺ and CD8⁺ T cells in response to recombinant E. coli-expressed Rv1860 protein of Mycobacterium tuberculosis (MTB) as well as protection of guinea pigs against a challenge with virulent MTB ...
Vijaya Satchidanandam +5 more
doaj +1 more source
mBio, 2022 Mycobacterium tuberculosis infects approximately one-third of the world's population, causing active tuberculosis (TB) in ~10 million people and death in ~1.5 million people annually. A potent vaccine is needed to boost the level of immunity conferred by
Qingmei Jia +3 more
doaj +1 more source
Frontiers in Immunology, 2020 While Baccillus Calmette-Guerin (BCG) is used worldwide, tuberculosis (TB) is still a global concern due to the poor efficacy of BCG. Novel vaccine candidates are therefore urgently required.
Si-Jing Liu +12 more
doaj +1 more source
CFP10: mFcγ2 as a novel tuberculosis vaccine candidate increases immune response in mouse [PDF]
Iranian Journal of Basic Medical Sciences, 2017 Objective(s): Despite treatment with antibiotics and vaccination with BCG, tuberculosis (TB) is still considered as one of the most important public health problems in the world.
Ali Asghar Baghani +10 more
doaj +1 more source